Epiodyne

San Francisco, US · 2 known investors

Epiodyne develops small-molecule opioids designed to optimize therapeutic outcomes, with initial focus on safer pain relief and improved opioid use disorder treatment with reduced addiction and respiratory depression risk. The company uses a platform approach to tune drug candidates across a spectrum from inhibitors to full agonists.

BiotechHealthtechMedical Devices